MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for magnesium sulfate; potassium chloride; sodium sulfate and what is the scope of freedom to operate?
Magnesium sulfate; potassium chloride; sodium sulfate
is the generic ingredient in one branded drug marketed by Azurity and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Two suppliers are listed for this compound.
Summary for MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Clinical Trials: | 32 |
| DailyMed Link: | MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE
Generic Entry Date for MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Assiut University | PHASE1 |
| Assiut University | PHASE3 |
| Cairo University | PHASE4 |
See all MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE clinical trials
Pharmacology for MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| SUTAB | Tablets | magnesium sulfate; potassium chloride; sodium sulfate | 1.479 g/0.225 g/ 0.188 g | 213135 | 1 | 2023-03-03 |
US Patents and Regulatory Information for MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | SUTAB | magnesium sulfate; potassium chloride; sodium sulfate | TABLET;ORAL | 213135-001 | Nov 10, 2020 | RX | Yes | Yes | 11,382,864 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Azurity | SUTAB | magnesium sulfate; potassium chloride; sodium sulfate | TABLET;ORAL | 213135-001 | Nov 10, 2020 | RX | Yes | Yes | 11,638,697 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Azurity | SUTAB | magnesium sulfate; potassium chloride; sodium sulfate | TABLET;ORAL | 213135-001 | Nov 10, 2020 | RX | Yes | Yes | 10,143,656 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch